Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seems about right. It’s been a long time since anyone showed any interest in our product. Even Biogen took a pass about 10 years ago. You would think Anavex would be all over the EMA request. Missing seems to have been giving himself cover right from the beginning of the EMA request by saying it will take a million pages. No guarantees seems spot on, IMO.
And just as we began to gain traction with the EMA with Alzheimer’s, instead of driving this forward, he switches to animal studies for Fragile X. He has done this before and the sp plummeted. It seems this guy is either a hopeless scatterbrain or he’s trying to build up interest to sell the company.
With Biogen’s sp taking a hit today, I don’t see our sp taking a similar hit to be sustainable. Maybe early in the day but Blarcamasine just took a major leap toward approval, IMO. It seems obvious, the EMA has more credibility than the FDA.
False. Clearly mislabeled. Should be:
Healthy Brain / Your Brain
We have the Safety. Missing needs to release
Data NOW to show Efficacy or lack thereof.
https://amp.theguardian.com/society/2024/mar/24/alzheimers-breakthrough-drugs-medicine-donanemab-aducanumab-lecanemab
From Yahoo
Major Holders
Breakdown
3.05% of Shares Held by All Insider
37.89% of Shares Held by Institutions
39.08% of Float Held by Institutions
196 Number of Institutions Holding Shares
Insider Roster
Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.
Individual or Entity
Most Recent Transaction
Date
Shares Owned as of Transaction Date
BOENISCH SANDRA (Officer and Treasurer
Sale
Jun 29, 2021
22,963
DONHAUSER PETER D.O. Director
Purchase
Jun 14, 2024
5,000
FAVUS ELLIOT J. M.D.
Director
Sale
May 21, 2021
LALACH HARVEY
President
Sale
May 29, 2012
550,000
MISSLING CHRISTOPHER U
Chief Executive Officer
Sale
Mar 28, 2024
1,250,210
SKARPELOS ATHANASIOS
Director
Sale
May 25, 2022
1,306,460
THOMAS STEFFEN PHD
Director
Purchase
May 15, 2024
5,000
WU PEI RU
Chief Operating Officer
Sale
Apr 25, 2006
--
YANG WU
Chief Executive Officer
Sale
Just came across this:
https://www.anavex.com/press-releases/anavex-life-sciences-receives-tga-special-access-scheme-approval-for-anavex%C2%AE2-73-(blarcamesine)-for-alzheimer%E2%80%99s-disease-patients-
So the potential for folks with Alzheimer Disease being on Blarcamasine for going on 9 years, is possible. Why never any follow-up on this group of people. Is this just the total incompetence of our CEO or is he a true fraud dressed up as a CEO?
Looks like the mm’s couldn’t wait for Misleading to speak tomorrow to bring the price down. Could we see double header?
Is Egis Pharm planning a Generic, a Biosimiliar or is it a new Inovative drug related to our Blarcamisine? Their newly issued Patent does say “New Drug.” No word of any business relationship with Egis from Anavex. I do recall Missling missed patenting A2-73 in 2014 and patented Anavex 2-73/Plus (Blarcamisine combined with Aracept). Missing seems to have zero respect for CNS Disease victims let alone shareholders. This new patent seems more of a go it alone plan than an upcoming partnership. All my opinion only.
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/generic-drug#:~:text=Generic%20drugs%20are%20usually%20approved,to%20establish%20safety%20and%20effectiveness.
Anavex Life Sciences Corp.
630 5th Avenue
20th Floor
New York, NY 10111
United States
844 689 3939
Why the thumbs up? This does not appear to be good news. Missing is a sorry az mf, IMHO. How much longer is our patent good for? This patent was granted to a generic pharmaceutical Company:
We are one of the leading generic pharmaceutical companies in Central Eastern Europe
The object of our invention was to develop a new, pharmaceutically acceptable form of the active ingredient
blarcamesine hydrochloride that would retain its uniformity during pharmaceutical processing (crushing, granulation,
The “million page” thing Missling talked about was surely just a figure of speech, IMO, coming from a guy overwhelmed by the upcoming approval by EMA and subsequent approval by the FDA. Jeesh. How much clearer can it be.
It’s hard to believe this is an approved drug. But then again, the unfortunate folks who develop cancer surely find themselves in a state of desperation at times. The possible side effects would make this a no go for me for PD and AD.
https://pharmatimes.com/news/us-study-suggests-bms-cancer-drug-could-target-parkinsons-causing-protein/
https://www.opdualag.com/results/side-effects?cid=sem_2243853&gclsrc=ds
And if you pick and choose which science to believe, then you don't believe in science
All those questions George. Almost looks like you, of all people, are going into full panic mode. No doubt we will see the 2’s sooon, very sooon, maybe tomorrow or maybe in a fortnight. Tip of the iceberg.
My personal research takes priority over anything I get from a physician.
It’s hard to understand the FDA is still approving amyloid removal mabs that end up with patients eventually getting worse and dying. Not all amyloid is bad. People with high amount of soluble amyloid never get AD even if they have amyloid plaque.
https://neurology.uw.edu/2024/02/29/the-illusion-of-progress-lecanemab-in-alzheimers-disease/
We need to hire more his guy:
When he used the buzzword "sleeper surprise..." he said the mabs don’t have the market on upcoming trials. He was referring to blacamasine. Even you might be surprised.
I didn’t hear her mention any specific company.
Good find George. Gotta give credit where credit is due.
You sound like Georgie.
I think he got $119K of $125K. It was also linked to stock performance.
Why TF are things taking so long with this company??????
Not that it matters, in the whole scheme of things, but Dr Misslings Annual Bonus is based on the calendar year not the fiscal year. It’s stated in the Annual Report, Section 11, I think.
But anyway, enjoy the holiday remembering all those who have gone before us, also keeping in mind, our Founding Fathers who gave us the freedoms and liberty that we have enjoyed for years but now seem to be slipping away.
I disagree with most of your bs but releasing the unfavorable Rett data on Jan 2nd still p’s me off. This was clearly an attempt to secure his annual bonus. It worked. Even if the law suit is a success, it won’t cost Missling a dime. Shareholders will be the ones paying the price.
We probably could all use it right now, to prevent or delay a number of age related diseases or at least slow down the aging process. A lot of its benefits were discovered during clinical trials. I think Missling even said it could be used like a daily vitamin. Much more to learn what else it does but I think we know enough for approval now. Right Now!
Most, if not all, of the new hire positions are remote positions. These hires give the illusion that wow, we’re really growing, working feverishly together in the lab to add final tweaks to quickly finish what needs to be finished to bring this product to the world. Just to be clear, we operate out of an office in NY.
It is already being administered for compassionate use. Is “Right to Try” only for terminally ill patients?
The FDA and EMA documents are being prepared in parallel, IMO, for Rett in the U.S. and AD for Europe. When approval for Rett Syndrome happens, off label for AD in the U.S. and Europe will happen overnight making the EMA process for AD a bureaucratic nightmare. Our little company will make the big time and Dr Missling, MA, PhD will gain genius status. All my opinion. Do your own due diligence. Or this could all be bs, also, IMO. Still kind of on the fence whether this is all for real or not. Still a coin flip for me.
Missing would gain Hero status if he has the completed documents for FDA Approval for AD and Rett Syndrome sitting on his desk and submits to FDA immediately upon FDA rule change.
https://stocktwits.com/MayoMobile
With a long history of stating total bs as fact, maybe he should apply for a job at some news media channel. He would fit right in. Or maybe some religion channel. A lot of them seem to have their own game going on.
Glad I got back in at $4.20
https://finance.yahoo.com/news/anavex-life-sciences-avxl-upgraded-160009326.html
That’s a lot of shares. I cannot totally believe Missling is as corrupt as he sometimes appears to be. Lack of transparency, missed deadlines and a seeming lack of ability to capture the talent of those he surrounds himself with certainly doesn’t add credibility to his resume. But, with that being said, there does seem to be changes happening in the FDA that could boost our chances of approval in the not too distant future. Rett and AD are still on the table, according to Missling. If they somehow find a way to cross the finish line with A2-73, 50 bucks per share will look like pocket change. All my personal opinion, fwiw, so don’t take it as investment advice. Maybe Missling will taper his ego a bit and let the professionals around him do their job.
This “growth strategy” term seems pretty general. But it could give the sp a significant boost if the “strategy” is to apply for EMA approval “next week”, FDA approval for Rett “next week” and Missling’s retirement “next week.” He seems to be all about the money so a sp boost would fall in line with him cashing out. Maybe not $5 to $100 but could be a significant rise. But, then again, maybe not.
Management will host a conference call on Thursday, May 9, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy.
Looks like a no win for AVXL. Looks like Misleading’s days as CEO are coming to an end. Could only be good for the company though, IMO.
https://fox2now.com/business/press-releases/globenewswire/9105826/avxl-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-anavex-life-sciences-corp-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit/#:~:text=When%20Anavex's%20prior%20misrepresentations%20and,of%20Anavex%20stock%20fell%20precipitously.